<DOC>
	<DOCNO>NCT02743975</DOCNO>
	<brief_summary>There need good visualization resection margin detection small tumor deposit surgery pancreatic cancer . Optical molecular image pancreatic ductal adenocarcinoma associate biomarkers promise technique accommodate need . The biomarker Vascular Endothelial Growth Factor ( VEGF-A ) overexpressed pancreatic cancer tissue versus normal tissue proven valid target molecular imaging . VEGF-A target monoclonal antibody bevacizumab . Monoclonal antibody label near-infrared ( NIR ) fluorescent dye IRDye800CW ( 800CW ) . The investigator hypothesize bevacizumab-800CW accumulates VEGF express cancer , enable pancreatic cancer visualization use NIR intraoperative camera system . In pilot intervention study investigator determine optimal dosage bevacizumab-800CW ( 4,5 10 , 25 50mg ) detect pancreatic cancer tissue intraoperatively .</brief_summary>
	<brief_title>Near-infrared Image Guided Surgery Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age â‰¥ 18 year . Patients clinical suspicion pancreatic head cancer schedule undergo surgical intervention curative intent World Health Organization ( WHO ) performance score 02 . Signed write informed consent Medical psychiatric condition compromise patient 's ability give inform consent . Other invasive malignancy Pregnant lactate woman . Documentation negative pregnancy test must available woman childbearing potential . Woman childbearing potential pre menopausal woman intact reproductive organ woman less two year menopause . Prior neoadjuvant chemo radiotherapy History infusion reaction bevacizumab monoclonal antibody therapy . Inadequately controlled hypertension without current antihypertensive medication Within 6 month prior inclusion : myocardial infarction , Transient Ischemic Attack , Cerebral Vascular Accident , pulmonary embolism , uncontrolled chronic hepatic failure , unstable angina pectoris . Anticoagulant therapy vitamine K antagonists Patients receive Class 1A ( quinidine , procainamide ) class III ( dofetilide , amiodarone , sotalol ) antiarrhythmic agent Evidence QTc ( correct QT interval ) prolongation pretreatment ECG ( great 44ms male great 450ms female ) Magnesium , potassium calcium low limit normal range .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>